Checkpoint blockade in esophagogastric cancer. Review uri icon

Overview

abstract

  • There are few effective treatment options for metastatic esophagogastric adenocarcinomas after progression on second-line chemotherapy. Immune checkpoint blockade therapy is a promising treatment strategy for selected advanced esophagogastric cancer, and the PD-1 inhibitor pembrolizumab has recently been approved for metastatic or recurrent gastric or gastroesophageal junction cancer that has progressed beyond second-line systemic therapy. We review the current data supporting immune checkpoint blockade therapy in advanced esophagogastric adenocarcinoma.

publication date

  • June 7, 2018

Research

keywords

  • Antibodies, Monoclonal
  • Esophagogastric Junction
  • Stomach Neoplasms

Identity

PubMed Central ID

  • PMC7891842

Scopus Document Identifier

  • 85053255556

Digital Object Identifier (DOI)

  • 10.1002/jso.25116

PubMed ID

  • 29878357

Additional Document Info

volume

  • 118

issue

  • 1